← Return to Does anyone have a solution to help manage Reclast side effects?

Discussion
Comment receiving replies
Profile picture for njhornung @normahorn

@estelle17
Reminds me of one of the 2024 Shkreli award winners. I saw an expanded explanation last year but not now.

"Amgen’s Lumakras Pricing: The pharmaceutical giant was criticized for promoting a 960mg dose of its cancer drug Lumakras, despite evidence that a lower 240mg dose offered the same efficacy with fewer side effects. The higher dose costs $180,000 more per patient annually."

Jump to this post


Replies to "@estelle17 Reminds me of one of the 2024 Shkreli award winners. I saw an expanded explanation..."

@normahorn

Never heard of the Shkreli awards. I am in awe of the concept and dismayed by the activities giving rise to the 'winners.' When put in this context, those activities confirm what most of us already know.

Those of us in the world of osteoporosis treatment are familiar with the name Amgen. Not surprised it was an award winner.

@normahorn Thank you. She did not really give me an answer. I did read somewhere that there is no evidence that a half dose works. Still thinking of getting g another opinion before doing it.